We conducted a single-center analysis of a cohort of patients with stage IV HNSCC who were treated with anti-PD-1/L1 or anti-CTLA-4 monoclonal antibodies (or both). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.